Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind Study Of The Morphine-Sparing Efficacy And Safety Of Parecoxib Sodium 40 Mg IV Followed By 20 Mg IV Every 12 Hours In The Treatment Of Pain Following Radical Prostatectomy.

Next Previous
Trial Profile

Randomized, Double-Blind Study Of The Morphine-Sparing Efficacy And Safety Of Parecoxib Sodium 40 Mg IV Followed By 20 Mg IV Every 12 Hours In The Treatment Of Pain Following Radical Prostatectomy.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Morphine (Primary) ; Parecoxib (Primary)
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 15 Dec 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
  • 18 Aug 2009 Planned end date changed from 1 Jun 2009 to 1 Jun 2011 as reported by ClinicalTrials.gov..
  • 10 Sep 2008 Actual start date changed from Nov 2006 to Jun 2009 as reported by Clinicaltrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top